• Journal of Digital Convergence
• /
• v.20 no.1
• /
• pp.47-54
• /
• 2022

The purpose of this study was to derive policy priorities for fostering the biopharmaceutical industry. In this study, the urgency and importance of the policy to foster the biopharmaceutical industry in Gyeonggi-do was investigated, and the priorities of the policy in the biopharmaceutical industry were analyzed through IPA analysis. As a result of the study, the top priority support tasks for the biopharmaceutical industry promotion policy were 'R&D support', 'Expert training', and 'commercialization support'. As a result of deriving policy priorities for each biopharmaceutical sector, 'R&D support' and 'Expert training' were found to be high in common, and differences in policy priorities for each industry such as cell therapy products and advanced bio-convergence products were confirmed. Also, as for the policy demand, R&D funding support, clinical trial support, and commercialization funding support were found to be high. Based on these results, the government's policy to foster the biopharmaceutical industry was supported with a focus on 'R&D support' and 'Expert training', and policy implications were drawn that customized support is needed in consideration of the characteristics of each industry field.

• Asian Journal of Innovation and Policy
• /
• v.8 no.2
• /
• pp.180-207
• /
• 2019

This article explores the historical evolutionary process of the biopharmaceutical industry of Korea, and how intentional and unintentional policy interventions have triggered the creation of the industry's system dynamics and paved the way for the generation of a few global leading products, including biosimilar, as well as next-generation therapeutics of gene and cell. The policies cover the simple technology transfer of API synthesis to overcome the endemic parasitic disease, new substance patent adoption and new drug development consortia, human resource development, various national initiatives influenced by the Human Genome Project, and venture promotion schemes. The scope and implementation tools under these policies have been aligned and refined to transform traditional fine chemical-based pharmaceuticals, to stimulate large companies' participation and to create technology-based venture companies in the biopharma business of Korea.

• Proceedings of the Plant Resources Society of Korea Conference
• /
• 2023.04a
• /
• pp.28-28
• /
• 2023

Archidium ohioense Schimp. ex Müll. Hal.는 국내 자생 정보가 부족했던 종으로 본 연구를 통해 경기도 연천군 전곡읍 간파리 감악산에서 신분포지를 확인하였다. A. ohioense가 속하는 Archidium Brid. (Archidiaceae)는 극지방을 제외한 아열대지역에서 온대지역까지 분포하며, 총 36종이 생육하는 것으로 알려져 있고, 최근 anti-inflammatory와 antisickling potentials에 관한 효능 연구가 수행되고 있다. A. ohioense의 잎은 난상피침형~삼각상피침형으로 잎가장자리는 밋밋하나 잎끝에 미세한 치돌기가 있다. 잎맥은 굵고 1개이며 잎끝까지 또는 짧게 돌출되어 있다. 중앙세포는 마름모형, 긴 선형의 마름모형이고, 익부세포는 마름모형에서 직사각형이다. 추후 분자생물학적인 연구 및 생태학적인 연구가 추가된다면 안정적인 자원화에 기여할 수 있을 것이라 사료된다.

• Korean Journal of Plant Resources
• /
• v.37 no.2
• /
• pp.130-136
• /
• 2024

Archidium Brid. (Archidiaceae), comprising a total of 35 species, is known to be widely distributed from subtropical to temperate regions, excluding the polar areas. The distribution of Archidium ohioense Schimp ex Müll. Hal. in Korea has been unclear. This study reports the collection of Archidium ohioense from Mt. Gamak, Yeoncheon-gun, Gyeonggi-do, South Korea. This species is distinguished from similar species by median cell, alar region, capsule. We provide detailed description, illustrations, photographs, and a key to related species.

• Journal of the Korean Society of Environmental Restoration Technology
• /
• v.20 no.6
• /
• pp.161-180
• /
• 2017

As the competition for securing cross-border biological sovereignty becomes intensified due to the adoption of the Nagoya Protocol, this study analyzed patent trends only for freshwater plants in order to secure national biological sovereignty. As a result, freshwater plants include a total of 68 genera and 128 species, and a total of 60 genera and 3,256 patents were surveyed. Among them, iris was the most industrialized, 14.71% followed by angelica(8.48%) and Mentha(6.94%). However, unconfirmed eight genera (Aneilema, Artemisia Cabomba, Nymphoides, Pistia stratiotes L., Pseudoraphis Griff., Ruppia) are not patented freshwater plants and it is expected that patent entry is high and barrier is low in the future. Based on patent results, Cooperative Patent Classification analysis was carried out and as a result, a total of 15 industry sectors were derived. And biopharmaceutical(30.24%) was found to be the most industrialized industry sector followed by agricultural chemistry (28.89%), biochemical industry (16.25%). In the biomedical industry, angelica(17.74%) was the most used and Iris (9.55%), Sium(20.56%) and angelica (20.48%) were found to be the most used in agricultural chemistry, biochemical industry and bio food industry, respectively. The analysis of detailed industry fields for 15 industry sectors showed that medicines of unknown structure containing substances from plants (37.77%), raw materials (46.57%) such as insect repellants, attracting agents and preparation of peptides(16.82%) with more than 21 amino acids were most frequently used in biopharmaceutical, agricultural chemistry and biochemical industry, respectively. This study is of significance as a basic data to know which freshwater plants are used in which field in order to secure biological sovereignty and patent analysis is considered necessary to continuously secure the biological sovereignty for freshwater plants.

• Proceedings of the Plant Resources Society of Korea Conference
• /
• 2023.04a
• /
• pp.29-29
• /
• 2023

특정도서(特定島嶼)의 다양한 자연생태계, 지형 또는 지질 등을 비롯한 자연환경의 보전에 관한 기본적인 사항을 정함으로써 현재와 미래의 국민 모두가 깨끗한 자연환경 속에서 건강하고 쾌적한 생활을 할 수 있도록 함을 목적으로 하는 '독도 등 도서지역의 생태계보전에 관한 특별법(도서생태계법)' 제6조 및 특정도서 보전기본계획(2015~2024)에 의거하여 한강유역환경청에서는 33개(강화군 8, 옹진군 23, 안산시 1, 화성시 1) 도서를 특정도서로 지정하여 관리하고 있다. 본 연구에서는 출입과 개발행위가 제한되어 있는 특정도서의 식물상 조사를 도서생태계법 제6조에 의거하여 수행하였고, 인근 유인도서와 식물상을 비교 기록하였다. 조사된 유인도서는 덕적도, 영흥도, 선재도, 측도, 문갑도, 소야도의 6개 도서이고, 무인도서는 특정도서로 지정된 33개 도서 전체를 대상으로 하였다. 무인도서에서는 90과 225속, 294종, 3아종, 22변종, 1품종, 총 320분류군이 기록되었다. 이 중 국 가적색목록은 지치(Lithospermum erythrorhizon), 이팝나무(Chionanthus retusus), 모새달(Phacelurus latifolius) 3분류군과 한반도 고유종은 새끼노루귀(Hepatica insularis) 등 3분류군이 확인되었으며, 메귀리(Avena fatua) 등 외래식물 24분류군과 돼지풀(Ambrosia artemisiifolia) 등 생태계교란식물 3분류군이 확인되었다. 대조군인 유인도서에서는 116과 350속, 532종, 7아종, 37변종, 3품종, 총 579분류군이 기록되었다. 이 중 선재도에서 멸종위기야생생물 II급 매화마름(Ranunculus trichophyllus var. kadzusensis)이 확인되었으며, 국가적색목록은 낙지다리(Penthorum chinense) 등 4분류군, 한반도 고유종은 할미밀 망(Clematis trichotoma) 등 7분류군이 확인되었으며, 미국자리공(Phytolacca americana) 등 53분류군의 외래식물과 가시박(Sicyos angulatus) 등 6분류군의 생태계교란식물이 확인되었다.

• Proceedings of the Membrane Society of Korea Conference
• /
• 1996.10a
• /
• pp.18-21
• /
• 1996

Virus and DNA removal in bio-drug manufacturing processes has received a great deal of attention in recent years. Removing of a virus using a membrane process is a promising method, because inactivated virus can be removed from the bio-drug and the process can be used as an additional and security inactivation after the method of general heat-inactivation of the virus in the bio-drug. The FDA and the biopharmaceutical industry have recently announced strict guidelines for impurities of virus and DNA contamination. The regulatory guidelines on residual amounts of DNA in mammalian cell culture products require DNA contamination of less than 100 pg/dose. Therefore, permeation and rejection of DNA through the porous membranes have become important in the application of DNA removal in bio-drug manufacturing using membrane technology. In this study, the permeation of DNA and chromatin through regenerated cellulose hollow fibers that have a mean pore diameter of 15 nm was investigated.

• Molecules and Cells
• /
• v.20 no.1
• /
• pp.17-29
• /
• 2005

Therapeutic antibodies represent one of the fastest growing areas of the pharmaceutical industry. There are currently 19 monoclonal antibodies in the market that have been approved by the FDA and over 150 in clinical developments. Driven by innovation and technological developments, therapeutic antibodies are the second largest biopharmaceutical product category after vaccines. Antibodies have been engineered by a variety of methods to suit a particular therapeutic use. This review describes the structural and functional characteristics of antibody and the antibody engineering for the generation and optimization of therapeutic antibodies.

• 한국벤처창업학회:학술대회논문집
• /
• 2022.04a
• /
• pp.25-30
• /
• 2022

Despite the importance of partnership for commercialization of innovations in startups, it is not easy for startups to persuade an established firm to collaborate on a completely novel idea. If information transfer about the innovations is too costly, startups may avoid pursuing radically new projects. Our paper examines the impact of policy signals on the novelty of the innovations pursued by startups. In the context of the Orphan Drug Act(ODA), we find that startups develop more radical therapies when policy signals help them to convince potential partners of the value of prospective therapies. While the likelihood of partnership increases, the timing of partnership is delayed in ODA-affected fields.

• Journal of Pharmaceutical Investigation
• /
• v.40 no.spc
• /
• pp.9-17
• /
• 2010

Polymorphism has been recognized to be a critical issue throughout the drug product development process. Most of solid phase drugs have polymorphism, which has generated a great deal of interest and the field has been evolving rapidly. Preferably, thermodynamically most stable form of a drug substance is selected to obtain consistent bioavailability over its shelf life and various storage conditions. Moreover, it has the lowest potential for conversion from one polymorphic form to another. However, metastable or amorphous forms may be used intentionally to induce faster dissolution rate for rapid drug absorption and higher efficacy. For pharmaceutical industry, polymorphism is one of the key activities in form selection process together with salt selection. This article introduces the main features in the investigation of solid form selection especially polymorphic behavior with thermodynamic backgrounds, physicochemical properties with solubility, dissolution, and mechanical properties, and characterization techniques for proper analysis. The final form can be recommended based on the physicochemical and biopharmaceutical properties and by the processability, scalability and safety considerations. Pharmaceutical scientists especially in charge of formulation need to be well aware of the above issues to assure product quality.